This study presents an innovative approach that utilizes polymers with different topologies and properties as potential matrices for the poorly water-soluble active pharmaceutical ingredient piribedil (PBD). We investigated amorphous solid dispersions (ASDs) as well as micellar systems composed of PBD and (i) the commercial amphiphilic copolymer Soluplus, (ii) self-synthesized hydrophilic linear PVP (linPVP), and (iii) self-synthesized hydrophilic star-shaped PVP (starPVP). Differential scanning calorimetry, X-ray diffraction, Fourier-transform infrared, and broadband dielectric spectroscopy were applied to gain comprehensive insights into the thermal and structural properties, intermolecular interactions, global molecular dynamics, and recrystallization of the API from the amorphous PBD-polymer ASDs. The primary objective was to evaluate the impact of the type and topology of macromolecules, as well as the composition of binary formulations, on the physical stability of PBD in the amorphous form, phase transition temperatures, the API's recrystallization rate, and ultimately, the release of drug in the prepared ASDs and micelles. Most importantly, our research led to the discovery of new polymorphic form (II) of PBD that has not been previously described in the scientific literature. We also revealed that ASDs containing hydrophilic PVP polymers exhibit the best performance in stabilizing the amorphous form of the API, with the starPVP systems showing the highest stabilization effect. In contrast, for micellar systems, Soluplus turned out to be the most suitable candidate in terms of forming the self-assembles of the lowest size distribution among all systems. The long-term stability of the amorphous drug in PBD-Soluplus micelles was higher compared to PBD-starPVP ASD. Moreover, an improvement in the bioavailability of the API contained in all tested formulations (binary and micellar systems) was observed, with PBD-starPVP micelles exhibiting the most desirable drug release profile within the polymer matrix, as well as the highest concentration of released drug. The obtained data highlight the crucial role of the type and topology/architecture of the polymer in the design of novel pharmaceutical formulations.

• Klíčová slova
• Soluplus copolymer, amorphous solid dispersions, bioavailability, drug delivery system, micellar systems, piribedil, polyvinylpyrrolidone, solubility, topology of polymers,
• MeSH
• biologická dostupnost MeSH
• diferenciální skenovací kalorimetrie metody   MeSH
• difrakce rentgenového záření metody   MeSH
• farmaceutická chemie metody   MeSH
• hydrofobní a hydrofilní interakce MeSH
• krystalizace MeSH
• micely MeSH
• piribedil * chemie   MeSH
• polyethylenglykoly chemie   MeSH
• polymery chemie   MeSH
• polyvinyly chemie   MeSH
• příprava léků metody   MeSH
• rozpustnost MeSH
• spektroskopie infračervená s Fourierovou transformací metody   MeSH
• stabilita léku MeSH
• uvolňování léčiv MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• micely MeSH
• piribedil * MeSH
• polyethylenglykoly MeSH
• polymery MeSH
• polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer MeSH Prohlížeč
• polyvinyly MeSH

BACKGROUND: Nanomedicine approaches for cancer therapy face significant challenges, including a poor tumor accumulation, limited therapeutic efficacy, and systemic toxicity. We hypothesized that controlling the clustering of poly(acrylic acid-co-maleic acid) (PAM)-coated superparamagnetic iron oxide nanoparticles (SPIONs) would enhance their magnetic properties for improved targeting, while enabling a pH-responsive drug release in tumor microenvironments. METHODS: PAM-stabilized SPION clusters were synthesized via arrested precipitation, characterized for physicochemical and magnetic properties, and evaluated for doxorubicin loading and pH-dependent release. A dual targeting approach combining antibody conjugation with magnetic guidance was assessed in cellular models, including a novel alternating magnetic field (AMF) pre-treatment protocol. RESULTS: PAM-SPION clusters demonstrated controlled size distributions (60-100 nm), excellent colloidal stability, and enhanced magnetic properties, particularly for larger crystallites (13 nm). The formulations exhibited a pH-responsive drug release (8.5% at pH 7.4 vs. 14.3% at pH 6.5) and a significant enhancement of AMF-triggered release (17.5%). The dual targeting approach achieved an 8-fold increased cellular uptake compared to non-targeted formulations. Most notably, the novel AMF pre-treatment protocol demonstrated an 87% improved therapeutic efficacy compared to conventional post-treatment applications. CONCLUSIONS: The integration of targeting antibodies, magnetic guidance, and a pH-responsive PAM coating creates a versatile theranostic platform with significantly enhanced drug delivery capabilities. The unexpected synergistic effect of the AMF pre-treatment represents a promising new approach for improving the therapeutic efficacy of nanoparticle-based cancer treatments.

• Klíčová slova
• alternating magnetic field, cancer therapy, drug delivery, hyperthermia, magnetic targeting, pH-responsive, superparamagnetic iron oxide nanoparticles, theranostic,
• MeSH
• akrylové pryskyřice * chemie   MeSH
• doxorubicin * chemie   farmakologie   MeSH
• koncentrace vodíkových iontů MeSH
• lékové transportní systémy MeSH
• lidé MeSH
• magnetické nanočástice oxidů železa * chemie   MeSH
• magnetické nanočástice * chemie   MeSH
• maleáty * chemie   MeSH
• nádorové buněčné linie MeSH
• nádory * farmakoterapie   MeSH
• nosiče léků chemie   MeSH
• uvolňování léčiv MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• akrylové pryskyřice * MeSH
• carbopol 940 MeSH Prohlížeč
• doxorubicin * MeSH
• magnetické nanočástice * MeSH
• maleáty * MeSH
• nosiče léků MeSH

Ruthenium(III) complexes are promising anticancer metallodrugs because of their antimetastatic (migrastatic) potential and significantly lower host toxicity than generally used platinum metallodrugs. On the other hand, the ruthenium(III) complexes generally show low solubility and stability in an aqueous environment but exhibit some toxicity associated with unspecific delivery. For these reasons, numerous ongoing studies deal with their encapsulation into various delivery systems to maximize their therapeutic efficacy. One of these systems can also be crystals of nontoxic metal-organic frameworks (MOFs). In this work, we studied incorporation of a bioactive ruthenium(III) complex (RuC) inside MOFs derived from γ-cyclodextrin (γ-CD) and biocompatible potassium ions, forming CD-MOF-1. Viability studies in vitro were carried out using spheroids of human hepatoblastoma cell line HepG2. These studies revealed that the RuC-CD-MOF-1 system provides effective cancer cell suppression through slow gradual release over a longer period (>10 days) while reducing acute cytotoxic effects associated with naked RuC. This combination was defined for further development and optimization as a drug-delivery platform for metallodrugs.

• MeSH
• buňky Hep G2 MeSH
• cyklodextriny * chemie   MeSH
• gama-cyklodextriny * chemie   MeSH
• komplexní sloučeniny * chemie   farmakologie   chemická syntéza   MeSH
• lidé MeSH
• molekulární struktura MeSH
• porézní koordinační polymery * chemie   farmakologie   chemická syntéza   MeSH
• proliferace buněk účinky léků   MeSH
• protinádorové látky * farmakologie   chemie   chemická syntéza   MeSH
• ruthenium * chemie   farmakologie   MeSH
• screeningové testy protinádorových léčiv MeSH
• viabilita buněk účinky léků   MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• cyklodextriny * MeSH
• gama-cyklodextriny * MeSH
• komplexní sloučeniny * MeSH
• porézní koordinační polymery * MeSH
• protinádorové látky * MeSH
• ruthenium * MeSH

INTRODUCTION: The immunosuppressive roles of galectin-3 (Gal-3) in carcinogenesis make this lectin an attractive target for pharmacological inhibition in immunotherapy. Although current clinical immunotherapies appear promising in the treatment of solid tumors, their efficacy is significantly weakened by the hostile immunosuppressive tumor microenvironment (TME). Gal-3, a prominent TME modulator, efficiently subverts the elimination of cancer, either directly by inducing apoptosis of immune cells or indirectly by binding essential effector molecules, such as interferon-gamma (IFNγ). METHODS: N-(2-Hydroxypropyl)methacrylamide (HPMA)-based glycopolymers bearing poly-N-acetyllactosamine-derived tetrasaccharide ligands of Gal-3 were designed, synthesized, and characterized using high-performance liquid chromatography, dynamic light scattering, UV-Vis spectrophotometry, gel permeation chromatography, nuclear magnetic resonance, high-resolution mass spectrometry and CCK-8 assay for evaluation of glycopolymer non-toxicity. Pro-immunogenic effects of purified glycopolymers were tested by apoptotic assay using flow cytometry, competitive ELISA, and in vitro cell-free INFγ-based assay. RESULTS: All tested glycopolymers completely inhibited Gal-3-induced apoptosis of monocytes/macrophages, of which the M1 subtype is responsible for eliminating cancer cells during immunotherapy. Moreover, the glycopolymers suppressed Gal-3-induced capture of glycosylated IFNγ by competitive inhibition to Gal-3 carbohydrate recognition domain (CRD), which enables further inherent biological activities of this effector, such as differentiation of monocytes into M1 macrophages and repolarization of M2-macrophages to the M1 state. CONCLUSION: The prepared glycopolymers are promising inhibitors of Gal-3 and may serve as important supportive anti-cancer nanosystems enabling the infiltration of proinflammatory macrophages and the reprogramming of unwanted M2 macrophages into the M1 subtype.

• Klíčová slova
• carbohydrate, galectin-3, glycopolymer, interferon-gamma, monocyte, tumor microenvironment,
• MeSH
• akrylamidy chemie   farmakologie   MeSH
• apoptóza účinky léků   MeSH
• galektin 3 * antagonisté a inhibitory   MeSH
• interferon gama * metabolismus   MeSH
• lidé MeSH
• makrofágy účinky léků   MeSH
• monocyty * účinky léků   MeSH
• nádorové mikroprostředí účinky léků   MeSH
• polymery * chemie   farmakologie   MeSH
• protinádorové látky * farmakologie   chemie   MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• akrylamidy MeSH
• galektin 3 * MeSH
• galektiny MeSH
• interferon gama * MeSH
• krevní proteiny MeSH
• LGALS3 protein, human MeSH Prohlížeč
• polymery * MeSH
• protinádorové látky * MeSH

Background: Efficient theranostic strategies concurrently bring and use both the therapeutic and diagnostic features, serving as a cutting-edge tool to combat advanced cancers. Goals of the Investigation: Here, we develop stimuli-sensitive theranostics consisting of tailored copolymers forming micellar conjugates carrying pyropheophorbide-a (PyF) attached by pH-sensitive hydrazone bonds, thus enabling the tumor microenvironment-sensitive activation of the photodynamic therapy (PDT) effect, fluorescence or phosphorescence. Results: The nanomedicines show superior anti-tumor PDT efficacy and huge tumor-imaging potential, while reducing their accumulation, and potentially side effects, in the liver and spleen. The developed theranostics exhibit clear selective tumor accumulation at high levels in the mouse sarcoma S180 tumor model with almost no PyF found in the healthy tissues after 48 h. Once in the tumor, illumination at λexc = 420 nm reaches the therapeutic effect due to the 1O2 generation. Indeed, an almost complete inhibition of tumor growth is observed up to 18 days after the treatment. Conclusion: The clear benefit of the specific PyF release and activation in the acidic tumor environment for the targeted delivery and tissue distribution dynamics was proved. Conjugates carrying pyropheophorbide-a (PyF) attached by pH-sensitive hydrazone bonds showed their excellent antitumor PDT effect and its applicability as advanced theranostics at very low dose of PyF.

• Klíčová slova
• HPMA polymers, fluorescence imaging, pH-responsive theranostics, photodynamic therapy, tumor-targeted nanomedicines,
• MeSH
• fotochemoterapie * metody   MeSH
• fotosenzibilizující látky terapeutické užití   MeSH
• hydrazony terapeutické užití   MeSH
• individualizovaná medicína MeSH
• myši MeSH
• nádorové buněčné linie MeSH
• nádorové mikroprostředí MeSH
• nádory * diagnostické zobrazování   farmakoterapie   patologie   MeSH
• polymery chemie   MeSH
• teranostická nanomedicína metody   MeSH
• zvířata MeSH
• Check Tag
• myši MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Názvy látek
• fotosenzibilizující látky MeSH
• hydrazony MeSH
• polymery MeSH

Microbial resistance is one of the main problems of modern medicine. Recently, antimicrobial peptides have been recognized as a novel approach to overcome the microbial resistance issue, nevertheless, their low stability, toxicity, and potential immunogenic response in biological systems have limited their clinical application. Herein, we present the design, synthesis, and preliminary biological evaluation of polymer-antibacterial peptide constructs. The antimicrobial GKWMKLLKKILK-NH2 oligopeptide (PEP) derived from halictine, honey bee venom, was bound to a polymer carrier via various biodegradable spacers employing the pH-sensitive or enzymatically-driven release and reactivation of the PEP's antimicrobial activity. The antibacterial properties of the polymer-PEP constructs were assessed by a determination of the minimum inhibitory concentrations, followed by fluorescence and transmission electron microscopy. The PEP exerted antibacterial activity against both, gram-positive and negative bacteria, via disruption of the bacterial cell wall mechanism. Importantly, PEP partly retained its antibacterial efficacy against Staphylococcus epidermidis, Escherichia coli, and Acinetobacter baumanii even though it was bound to the polymer carrier. Indeed, to observe antibacterial activity similar to the free PEP, the peptide has to be released from the polymer carrier in response to a pH decrease. Enzymatically-driven release and reactivation of the PEP antimicrobial activity were recognized as less effective when compared to the pH-sensitive release of PEP.

• Klíčová slova
• HPMA copolymers, antimicrobial peptides, bacteria, drug delivery,
• Publikační typ
• časopisecké články MeSH

Nanomedicines are considered next generation therapeutics with advanced therapeutic properties and reduced side effects. Herein, we introduce tailored linear and star-like water-soluble nanosystems as stimuli-sensitive nanomedicines for the treatment of solid tumors or hematological malignancies. The polymer carrier and drug pharmacokinetics were independently evaluated to elucidate the relationship between the nanosystem structure and its distribution in the body. Positron emission tomography and optical imaging demonstrated enhanced tumor accumulation of the polymer carriers in 4T1-bearing mice with increased tumor-to-blood and tumor-to-muscle ratios. Additionally, there was a significant accumulation of doxorubicin bound to various polymer carriers in EL4 tumors, as well as excellent in vivo therapeutic activity in EL4 lymphoma and moderate efficacy in 4T1 breast carcinoma. The linear nanomedicine showed at least comparable pharmacologic properties to the star-like nanomedicines regarding doxorubicin transport. Therefore, if multiple parameters are considered such as its optimized structure and simple and reproducible synthesis, this polymer carrier system is the most promising for further preclinical and clinical investigations.

• Klíčová slova
• Biodistribution, Cancer, Drug delivery, HPMA, Polymeric carriers, Positron emission tomography,
• MeSH
• doxorubicin farmakokinetika   MeSH
• modely nemocí na zvířatech MeSH
• myši MeSH
• nádorové buněčné linie MeSH
• nanomedicína MeSH
• nosiče léků * chemie   MeSH
• polymery * chemie   MeSH
• zvířata MeSH
• Check Tag
• myši MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Research Support, N.I.H., Extramural MeSH
• Názvy látek
• doxorubicin MeSH
• nosiče léků * MeSH
• polymery * MeSH

Advanced drug delivery micro- and nanosystems have been widely explored due to their appealing specificity/selectivity, biodegradability, biocompatibility, and low toxicity. They can be applied for the targeted delivery of pharmaceuticals, with the benefits of good biocompatibility/stability, non-immunogenicity, large surface area, high drug loading capacity, and low leakage of drugs. Cardiovascular diseases, as one of the primary mortalities cause worldwide with significant impacts on the quality of patients' life, comprise a variety of heart and circulatory system pathologies, such as peripheral vascular diseases, myocardial infarction, heart failure, and coronary artery diseases. Designing novel micro- and nanosystems with suitable targeting properties and smart release behaviors can help circumvent crucial challenges of the tolerability, low stability, high toxicity, and possible side- and off-target effects of conventional drug delivery routes. To overcome different challenging issues, namely physiological barriers, low efficiency of drugs, and possible adverse side effects, various biomaterials-mediated drug delivery systems have been formulated with reduced toxicity, improved pharmacokinetics, high bioavailability, sustained release behavior, and enhanced therapeutic efficacy for targeted therapy of cardiovascular diseases. Despite the existing drug delivery systems encompassing a variety of biomaterials for treating cardiovascular diseases, the number of formulations currently approved for clinical use is limited due to the regulatory and experimental obstacles. Herein, the most recent advancements in drug delivery micro- and nanosystems designed from different biomaterials for the treatment of cardiovascular diseases are deliberated, with a focus on the important challenges and future perspectives.

• Klíčová slova
• advanced delivery systems, biocompatibility, cardiovascular diseases, drug delivery nanosystems, targeted drug delivery,
• MeSH
• biokompatibilní materiály MeSH
• kardiovaskulární nemoci * farmakoterapie   MeSH
• lékové transportní systémy MeSH
• léky s prodlouženým účinkem MeSH
• lidé MeSH
• příprava léků MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• přehledy MeSH
• Názvy látek
• biokompatibilní materiály MeSH
• léky s prodlouženým účinkem MeSH

Biodegradable nanomedicines are widely studied as candidates for the effective treatment of various cancerous diseases. Here, we present the design, synthesis and evaluation of biodegradable polymer-based nanomedicines tailored for tumor-associated stimuli-sensitive drug release and polymer system degradation. Diblock polymer systems were developed, which enabled the release of the carrier drug, pirarubicin, via a pH-sensitive spacer allowing for the restoration of the drug cytotoxicity solely in the tumor tissue. Moreover, the tailored design enables the matrix-metalloproteinases- or reduction-driven degradation of the polymer system into the polymer chains excretable from the body by glomerular filtration. Diblock nanomedicines take advantage of an enhanced EPR effect during the initial phase of nanomedicine pharmacokinetics and should be easily removed from the body after tumor microenvironment-associated biodegradation after fulfilling their role as a drug carrier. In parallel with the similar release profiles of diblock nanomedicine to linear polymer conjugates, these diblock polymer conjugates showed a comparable in vitro cytotoxicity, intracellular uptake, and intratumor penetration properties. More importantly, the diblock nanomedicines showed a remarkable in vivo anti-tumor efficacy, which was far more superior than conventional linear polymer conjugates. These findings suggested the advanced potential of diblock polymer conjugates for anticancer polymer therapeutics.

• Klíčová slova
• HPMA conjugate, anticancer, diblock conjugate, drug delivery, pirarubicin,
• Publikační typ
• časopisecké články MeSH

Over the last decades, the global life expectancy of the population has increased, and so, consequently, has the risk of cancer development. Despite the improvement in cancer therapies (e.g., drug delivery systems (DDS) and theranostics), in many cases recurrence continues to be a challenging issue. In this matter, the development of nanotechnology has led to an array of possibilities for cancer treatment. One of the most promising therapies focuses on the assembly of hierarchical structures in the form of nanoclusters, as this approach involves preparing individual building blocks while avoiding handling toxic chemicals in the presence of biomolecules. This review aims at presenting an overview of the major advances made in developing nanoclusters based on polymeric nanoparticles (PNPs) and/or inorganic NPs. The preparation methods and the features of the NPs used in the construction of the nanoclusters were described. Afterwards, the design, fabrication and properties of the two main classes of nanoclusters, namely noble-metal nanoclusters and hybrid (i.e., hetero) nanoclusters and their mode of action in cancer therapy, were summarized.

• Klíčová slova
• cancer therapy, drug delivery, inorganic nanoparticles, nanoclusters, polymeric nanoparticles, theranostics,
• Publikační typ
• časopisecké články MeSH
• přehledy MeSH